BOSTON, July  01, 2026  (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) (&#34;Damora&#34;), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced

DMRA

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Grants 453,500 Stock Options to Nine New Hires

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>BOSTON, July  01, 2026  (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) (&amp;#34;Damora&amp;#34;), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Damora Therapeutics granted inducement stock options to nine new hires totaling 453,500 shares at a $26.01 strike, with a 10-year term and 25% vesting after one year. The grants, approved under Nasdaq Rule 5635(c)(4), signal ongoing hiring ahead of 2026 clinical development and could modestly dilute existing holders if exercised; near-term price impact should be limited.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Nine new hires granted inducement options totaling 453,500 shares at $26.01 strike.</li><li>Options vest 25% after one year, then monthly over 36 months.</li><li>10-year term under the 2022 Damora Inducement Plan.</li><li>Approved as inducements under Nasdaq Rule 5635(c)(4).</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Damora Therapeutics, Inc. (DMRA)</strong>: Inducement option grants to nine new hires; may dilute equity pool over time.</li><li><strong>Nasdaq Listing Rule 5635(c)(4) (N/A)</strong>: Regulatory framework cited for inducement grants; guides compensation practices.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The news centers on equity-based compensation to support talent, signaling ongoing expansion efforts ahead of 2026 clinical development.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Nine new hires receive 453,500 options at $26.01 strike, potential dilution.</li><li>Vesting: 25% after 1 year, then monthly vesting for 36 months.</li><li>10-year term; long tail for potential dilution.</li><li>Regulatory framework: Nasdaq Rule 5635(c)(4) underpinning inducement grants.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Grant date: July 1, 2026.</li><li>Number of new hires: nine.</li><li>Aggregate options: 453,500 shares.</li><li>Option strike price: $26.01 per share.</li><li>Vesting schedule: 25% after 1 year, then monthly over 36 months; 10-year term.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral to mildly bullish over 6–12 months as 2026 clinical milestones could drive upside, with dilution risk.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="left">BOSTON, July  01, 2026  (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/DMRA">DMRA</a>) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to nine newly-hired, non-executive employees on July 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).</p>  <p>The inducement grants consist of non-qualified stock options to purchase an aggregate of 453,500 shares of Damora’s common stock with a 10-year term and an exercise price of $26.01 per share. All of the options vest as to 25% on the first anniversary of the employees’ start date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of a non-qualified stock option award agreement.</p>  <p><strong>About Damora Therapeutics</strong></p>  <p>Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=DMZL-HUhXzTshcaVD2oq1wBLMsrFFH3-E5srsM7Ek77_lyAAekmkLeHeNRXL5cS_TzBzM3xhLhiuGKl4sEOQhDUY4U2OFgD5ksblX_D61VI=" rel="nofollow" target="_blank">www.damoratx.com</a> or follow us on LinkedIn.</p>  <p>Media Contact:<br></br>Lia Dangelico<br></br>Deerfield Group<br></br><a href="https://www.globenewswire.com/Tracker?data=Av0aH9Xl_-UQENGVHdgcSPsxdf9EoBT-DEWe2CO2bs8kaTgMtoJioFQGSdRZ-_ovNBWO-IdKZd_JeYhkWJsMtF7k5KMnoT8dZUiWguzFi2CaV7jbumMlmy3KERZbt30AytCs2nYegyRaQyYesE8SDQ==" rel="nofollow" target="_blank">lia.dangelico@deerfieldgroup.com</a></p>  <p>Investor Contact:<br></br>Brian Ritchie<br></br>LifeSci Advisors<br></br><a href="https://www.globenewswire.com/Tracker?data=5Ao9nH01DSsA2AdqPSRKnW0rtTTHApqbkXcJgYS8CV5gpiWZSK1DQS5t_yni2pZ8xzXF6UybLVfdjTVL1nmiMDJLjyvlbxy_PP9kSWjzXhfpGh4V1RTNSLB0TufHSX2G" rel="nofollow" target="_blank">britchie@lifesciadvisors.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc1NTcyOSM3Njg3MzQzIzUwMDA2OTk5Nw=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NTgyYzVmNTAtODgzMy00YTA4LTg1ZGEtZDhjNDNiZjg5MWEwLTUwMDA2OTk5Ny0yMDI2LTA3LTAxLWVu/tiny/Damora-Therapeutics-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/547722cf-495b-4464-97a9-35bea3fa5d15"><img src="https://ml.globenewswire.com/media/547722cf-495b-4464-97a9-35bea3fa5d15/small/damora-rgb-png.png" border="0" width="150" height="37" alt="Primary Logo"></img></a></p>

Damora Therapeutics granted inducement stock options to nine new hires totaling 453,500 shares at a $26.01 strike, with a 10-year term and 25% vesting after one year. The grants, approved under Nasdaq Rule 5635(c)(4), signal ongoing hiring ahead of 2026 clinical development and could modestly dilute existing holders if exercised; near-term price impact should be limited.

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News